Overview

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-04-03

Target enrollment:

Participant gender:

Summary

This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab administration at Week 25). The number of visits will be 23 or 21 visits for participants who decide to continue amlitelimab therapy in the long-term extension study LTS17367 (RIVER-AD) study.

Phase:

PHASE1

Details

Lead Sponsor:

Sanofi

Treatments:

Caffeine
Metoprolol
Midazolam
Omeprazole
Warfarin